Skip to main content

Table 1 Baseline characteristics of the patients with mono-CA-BSI or mixed-CA/B-BSIs

From: Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections

Characteristics Total(n = 117) Mono-CA-BSI(n = 93) Mixed-CA/B-BSIs(n = 24) Pvalue
Age, median years (IQR) 68 (59,75) 69 (59,76) 64 (47,74) 0.399
Male sex [n (%)] 68 (58.1%) 53 (56.9%) 15 (62.5%) 0.626
APACHE II score at the onset of candidemia (IQR) 17.0 (11.5,24.5) 17.0 (12.0,24.0) 17.5 (10.0,26.5) 0.863
SOFA score at the onset of candidemia (IQR) 6.0 (2.0,9.0) 5.0 (2.0,9.0) 6.5 (2.0,9.8) 0.494
Prior ICU stay (days) (IQR) 3.0 (0.0,14.0) 1.0 (0.0,11.0) 12.0 (8.0,17.8) 0.001
Prior hospital stay (days) (IQR) 14.0 (4.5,27.5) 12.0 (2.0,26.5) 19.0 (12.0,30.8) 0.031
Prior ventilation mechanical ventilation (days) (IQR) 1.0 (0.0,13.0) 1.0 (0.0,10.0) 11.0 (0.3,24.5) 0.013
Underlying disease [n (%)]
 Diabetes mellitus 28 (23.9%) 23 (24.7%) 5 (20.8%) 0.690
 Chronic cardiac dysfunction 24 (20.5%) 16 (17.2%) 8 (33.3%) 0.144
 Chronic obstructive pulmonary disease 5 (4.3%) 5 (5.4%) 0 (0%) 0.552
 Chronic renal insufficiency 9 (7.7%) 8 (8.6%) 1 (4.2%) 0.766
 Chronic hepatic insufficiency 14 (12.0%) 13 (14.0%) 1 (4.2%) 0.333
 Solid tumour 33 (28.2%) 28 (30.1%) 5 (20.8%) 0.368
 Haematological malignancy 1 (0.9%) 1 (1.1%) 0 (0%) > 0.999
 Trauma 19 (16.2%) 14 (15.1%) 5 (20.8%) 0.708
 Burn injury 4 (3.4%) 2 (2.2%) 2 (8.3%) 0.186
 Transplant 14 (12.0%) 11 (11.8%) 3 (12.5%) > 0.999
Immunocompromised [n (%)]
 Immunosuppressant therapy 6 (5.1%) 6 (6.5%) 0 (0.0%) 0.448
 Steroid therapy 6 (5.1%) 6 (6.5%) 0 (0.0%) 0.448
 Chemotherapy/radiation 7 (6.0%) 7 (7.5%) 0 (0.0%) 0.366
 Neutropenia 4 (3.4%) 3 (3.2%) 1 (4.2%) > 0.999
Blood transfusion [n (%)] 40 (34.2%) 30 (32.2%) 10 (41.7%) 0.386
Hospitalization ward [n (%)]
 Medical 11 (9.4%) 11 (11.8%) 0 (0.0%) 0.168
 Surgical 28 (23.9%) 24 (25.8%) 4 (16.7%) 0.349
 ICU 78 (66.7%) 58 (62.4%) 20 (83.3%) 0.052
Nosocomial infection [n (%)] 112 (95.7%) 88 (94.6%) 24 (100%) 0.552
Life-sustaining treatments ≥24 h [n (%)]
 Invasive mechanical ventilation 65 (60.2%) 47 (54.7%) 18 (81.8%) 0.020
 Vasopressor 45 (38.5%) 34 (36.6%) 11 (45.8%) 0.405
 CRRT 30 (25.6%) 20 (21.5%) 10 (41.7%) 0.044
Catheterisation a [n (%)]
 Central venous catheterb 106 (90.6%) 83 (89.2%) 23 (95.8%) 0.553
  Hemodialysis catheterc 27 (23.1%) 17 (18.3%) 10 (41.7%) 0.015
  PICC 13 (11.1%) 10 (10.8%) 3 (12.5%) > 0.999
  Peripheral arterial catheters 37 (31.6%) 29 (31.2%) 8 (33.3%) 0.840
 Drainage tube 77 (65.8%) 59 (63.4%) 18 (75.0%) 0.287
 Urethral catheter 106 (90.6%) 85 (91.4%) 21 (87.5%) 0.848
Presence of two or more central venous catheters 36 (30.8%) 24 (25.8%) 12 (50.0%) 0.022
Total parenteral nutrition [n (%)] 85 (72.6%) 65 (69.9%) 20 (83.3%) 0.188
Hypoproteinemia [n (%)] 49 (41.9%) 37 (39.8%) 12 (50.0%) 0.366
Surgery [n (%)] 77 (65.8%) 59 (63.4%) 18 (75.0%) 0.287
Abdominal 39 (33.3%) 32 (34.4%) 7 (29.2%) 0.627
  1. Notes: Bold, indicates P < 0.05
  2. Abbreviations: IQR interquartile range, COPD chronic obstructive pulmonary disorder, SOFA sequential organ failure assessment, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, CRRT continuous renal replacement therapy, PICC Peripherally inserted central catheters
  3. aIncluded patients who were required to be catheterised within 2 weeks of the first positive sample, regardless of whether or not the catheter was removed before diagnosis
  4. bNon-tunneled central venous catheters such as subclavian, internal jugular and femoral venous catheters excluding hemodialysis catheter and PICC
  5. cNon-tunneled temporary dialysis catheter